Continued recovery from the Covid-19 pandemic resulted in strong growth for Abbott in Q2 of 2021. Credit: US Secretary of Defense on Wikimedia.

Abbott has reported sales of $10.2bn for the second quarter (Q2) of 2021, as against $7.32bn in the Q2 last year, up 39.5% on a reported basis and 35% on an organic basis.

The GAAP diluted earnings per share (EPS) was $0.66 in Q2 ended 30 June 2021, a surge of 120% compared to $0.30 during the year-ago quarter.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Adjusted diluted EPS, excluding specified items, was $1.17 in the second quarter of this year, indicating a 105.3% increase from Q2 2020.

The net earnings rose by 121.5% to $1.19bn in the Q2 of 2021 as compared to $537m in Q2 of 2020.

Abbott noted that the diagnostics sales rose to $3.2bn by 62.8% on a reported basis and 57.2% on an organic basis this quarter.

The international sales linked to Covid-19 testing stood at $1.3bn in the second quarter of 2021.

This growth was driven by merged sales of $1bn from Abbott’s BinaxNOW, Panbio and ID NOW rapid testing platforms.

In Q2 2021, global diagnostics sales, excluding Covid-19 testing-linked sales, reflected a 42.5% growth on a reported basis and 37.2% on an organic basis.

As against 2019, Core Laboratory and Molecular Diagnostics sales, excluding Covid-19 testing, showed a rise of 6.8% and 8.3%, respectively, on a reported basis in the Q2 of 2021 and 4.2% and 6.5%, respectively, on an organic basis.

Medical devices sales this quarter witnessed a growth of 51.3% on a reported basis and 45.1% on an organic basis, reaching a total of $3.6bn.

Furthermore, medical devices sales rose by 19.2% on a reported basis and 15.6% on an organic basis in the second quarter versus pre-pandemic sales in 2019. This rise was caused by double-digit growth in electrophysiology, heart failure, structural heart and diabetes care business.

In addition, global sales reflected a 12.3% increase on a reported basis and 11.3% on an organic basis in Q2 2021 compared to pre-pandemic sales in 2019. This data excludes sales linked to Covid-19 testing.

Abbott president and CEO Robert Ford said: “We’re achieving very strong growth across our portfolio.

“Perhaps most impressively, excluding Covid testing-related sales, our sales grew more than 11% on an organic basis compared to pre-pandemic levels in the second quarter of 2019, which demonstrates the fundamental strength of our performance.”

Robust growth in the Q2 of 2021 was led by continued recovery from the Covid-19 pandemic, the company said.

Abbott has projected its 2021 diluted EPS from continuing operations under GAAP of $2.75 to $2.95.

The full-year adjusted diluted EPS from continuing operations will be $4.30 to $4.50, indicating a robust double-digit growth compared to the previous year.

In April, Abbott reported sales of $10.5bn for the first quarter ended 31 March, with increases of 35.3% on a reported basis and 32.9% on an organic basis.